Conversely, inhibiting ATG4B restores PRMT1‐mediated MRE11 methylation, enhances the DDR, reduces mutation load, and significantly prolongs survival in a murine AML model [84]. The gene discussed is PRMT1; the disease is acute myeloid leukemia.